Literature DB >> 18160003

Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings.

Didier K Ekouevi1, André Inwoley, Besigin Tonwe-Gold, Christine Danel, Renaud Becquet, Ida Viho, François Rouet, François Dabis, Xavier Anglaret, Valériane Leroy.   

Abstract

We studied whether the use of T-lymphocyte CD4 (CD4) absolute count instead of CD4 percentage could affect the decision process regarding HAART initiation in African HIV-infected pregnant women. A prospective cohort in Abidjan, Côte d'Ivoire before HAART was available. Participating women received a perinatal antiretroviral prophylaxis (zidovudine + single-dose of nevirapine). CD4 count and percentage were measured by flow cytometry at baseline (32 weeks of amenorrhea) and at 1 month after delivery. A signed-rank test was used to compare the distributions of the CD4 absolute count and percentage values. A total of 325 HIV-1-infected pregnant women were included. At baseline, their median CD4 count was 355 cells/mm(3) and the median CD4 percentage was 24.8%; 17.8% of women had a CD4 count <200 cells/mm(3) and 14.8 % had a CD4 percentage <15%. One month after delivery, the median CD4 count was 489 cells/mm(3) (vs. baseline: p < 0.001), the median CD4 percentage was 25.6% (vs. baseline: p = 0.107), 9.5% of women had CD4 count <200 cells/mm(3) (vs. baseline: p < 0.001), and 15.1% of women had a CD4 percentage <15% (vs. baseline: p = 0.823). When combining the CD4 count and the WHO clinical stage, the proportion of women who met the WHO 2006 criteria for initiating HAART was 28.3% at baseline but 17.2% only at 1 month after delivery (p < 0.001). Between the prepregnancy and the postdelivery periods, the CD4 count experienced a significant increase, whereas the CD4 percentage remained unchanged. To accurately target the most appropriate time to start HAART, the CD4 percentage could be more reliable than the absolute count in sub-Saharan African pregnant women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160003     DOI: 10.1089/aid.2007.0059

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  19 in total

1.  Postpartum plasma CD4 change in HIV-positive women: implications for timing of HAART initiation.

Authors:  Ai Koyanagi; Andrea J Ruff; Lawrence H Moulton; Robert Ntozini; Kuda Mutasa; Peter Iliff; Jean H Humphrey
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

2.  Pregnancy outcomes in women with advanced HIV infection in Italy.

Authors:  Silvia Baroncelli; Enrica Tamburrini; Marina Ravizza; Carmela Pinnetti; Serena Dalzero; Manuela Scatà; Alessandra Crepaldi; Giuseppina Liuzzi; Atim Molinari; Antonella Vimercati; Anna Maccabruni; Daniela Francisci; Elena Rubino; Marco Floridia
Journal:  AIDS Patient Care STDS       Date:  2011-09-23       Impact factor: 5.078

3.  Risk for Speech and Language Impairments in Preschool Age HIV-exposed Uninfected Children With In Utero Combination Antiretroviral Exposure.

Authors:  Mabel L Rice; Jonathan S Russell; Toni Frederick; Murli Purswani; Paige L Williams; George K Siberry; Sean M Redmond; Howard J Hoffman; Tzy-Jyun Yao
Journal:  Pediatr Infect Dis J       Date:  2018-07       Impact factor: 2.129

4.  Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.

Authors:  Adriana Weinberg; Jeri E F Harwood; Elizabeth J McFarland; Jennifer Pappas; Jill Davies; Kay Kinzie; Emily Barr; Suzanne Paul; Carol Salbenblatt; Elizabeth Soda; Anna Vazquez; Charles A Peloquin; Myron J Levin
Journal:  Infect Dis Obstet Gynecol       Date:  2010-01-10

5.  Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.

Authors:  Erika Aaron; Mirjam-Colette Kempf; Shannon Criniti; Ellen Tedaldi; Ed Gracely; Amy Warriner; Ritu Kumar; Laura H Bachmann
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

6.  Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.

Authors:  Patrick A Coffie; Besigin Tonwe-Gold; Aristophane K Tanon; Clarisse Amani-Bosse; Gédéon Bédikou; Elaine J Abrams; François Dabis; Didier K Ekouevi
Journal:  BMC Infect Dis       Date:  2010-06-24       Impact factor: 3.090

7.  Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.

Authors:  Risa M Hoffman; Erin Leister; Deborah Kacanek; David E Shapiro; Jennifer S Read; Yvonne Bryson; Judith S Currier
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

8.  Factors associated with desire for children among HIV-infected women and men: a quantitative and qualitative analysis from Malawi and implications for the delivery of safer conception counseling.

Authors:  Paul Kawale; Deborah Mindry; Stephanie Stramotas; Peter Chilikoh; Ann Phoya; Katherine Henry; David Elashoff; Perry Jansen; Risa Hoffman
Journal:  AIDS Care       Date:  2013-11-06

9.  Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women.

Authors:  Elizabeth R Brown; Phelgona Otieno; Dorothy A Mbori-Ngacha; Carey Farquhar; Elizabeth M Obimbo; Ruth Nduati; Julie Overbaugh; Grace C John-Stewart
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

Review 10.  Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings.

Authors:  Renaud Becquet; Didier K Ekouevi; Elise Arrive; Jeffrey S A Stringer; Nicolas Meda; Marie-Laure Chaix; Jean-Marc Treluyer; Valériane Leroy; Christine Rouzioux; Stéphane Blanche; François Dabis
Journal:  Clin Infect Dis       Date:  2009-12-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.